NCT01775930View on ClinicalTrials.gov

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 18, 2019

Study Completion Date

January 18, 2019

Conditions
Kidney Cancer
Interventions
DRUG

Carfilzomib

20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Onyx Therapeutics, Inc.
All Listed Sponsors
collaborator

Onyx Therapeutics, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER